1-(3,4-methylenedioxybenzyl)-piperazine (MDBP), a piperazine designer drugs has been abused globally for the past few years.  The current literature on MDBP have revealed the techniques used for MDBP screening and quantification.  Furthermore, effect of MDBP on myocytes, hepatocytes, and Caenorhabditis elegans have been studied.  However, there are very few in silico, in vitro and in vivo studies that has investigated the pharmacodynamic properties and dopaminergic neuropharmacological profile of MDBP.  Hence, in this study, we investigated the pharmacodynamic properties and in vitro dopaminergic neuropharmacological effects of MDBP.  N27 dopaminergic neuronal cells were used in the current study to elucidate the effect of MDBP on dopaminergic neuronal viability, ROS & RNS generation, hydrogen peroxide, nitrite & Lipid peroxide production, glutathione & NADH content, and the activities of various enzymes such as mitochondrial Complex-I, Complex-IV, cyclooxygenase, interleukin converting enzyme, caspases (3,8,9), monoamine oxidase and tyrosine hydroxylase.  These markers enables to determine the effect of MDBP on oxidative stress, mitochondrial function, inflammation, apoptosis. and dopaminergic neurotransmission).  MDBP exhibited significantly lower in vitro dopaminergic neurotoxicity as compared to 3-TFMPP.  MDBP had no significant effect on tyrosine hydroxylase activity, interestingly, it inhibited the activity of monoamine oxidase significantly.   Similarly, it had no deleterious effect on the mitochondrial function and had no significant effect on the markers of apoptosis and inflammation.  Due to the above effects, MDBP might minimal dopaminergic neurotoxic effects.  Thus, MDBP with additional valid in vivo studies might be a prospective prophylactic or therapeutic medication to treat various human and animal diseases.